PSAT1 and breast carcinoma: Because our goal was to identify “loss-of-function” cases, in which pathway redundancy is limited by lineage-specific gene expression, we have identified a potentially more tractable opportunity to target serine metabolism in luminal, not basal, breast cancer, in which serine biosynthesis is naturally limited by the hypermethylation of the PSAT1 gene.